CPHI Webinar Series

Biosimilars in Oncology

20th October, 2021
4pm CET / 10am EST
Biosimilars in Oncology: what will this webinar address?

The availability of of biologic therapies to treat oncology disease conditions has led to improved clinical outcomes, but the high cost can create barriers and disparities in treatment access, and therefore outcomes. The use of biosimilars can improve patients' access to care by decreasing treatment costs and creating price competition between the originator product and biosimilar competitors.

When you attend this webinar, you get answers to these questions:
  • What is the current landscape of biosimilars in oncology?
  • How do biosimilar approvals and market access differ between the United States and Europe?
  • What is interchangeability and what is its impact?
  • What are the barriers to uptake of biosimilars in oncology?
  • What is the future of biosimilars in oncology?
Rachel Sliman
Senior Director - Data

Rachel Sliman is the Product Manager for the Context Matters Market Access Platform (MAP) at Clarivate, where she helps to build the platform and user experience around Clarivate's data model. Prior to her role as Product Manager, Rachel was the Senior Director of Analytic Services, where she coordinated the management and execution of custom analytical projects, and was the Director of Data for MAP, with an expertise in regulatory data. Rachel completed an MPH in Reproductive and Family Health from the Columbia University Mailman School of Public Health. Rachel also holds a BA in sociology and women’s studies from Tufts University.

This webinar is brought to you by

Biosimilars in Oncology
  • 20th October, 2021
  • 4pm CET / 10am EST
  • 60 minutes
  • Free
CPHI Newsletter

Get the latest from CPHI in your inbox every week.

You understand that your information will be used in accordance with our Privacy Policy, and that you may withdraw your permission to receive any of our communications at any time by clicking on the Unsubscribe link in the Newsletters or opting out on our unsubscribe page page.